Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Acquisition of BTK C481S Produces Resistance to Ibrutinib in MYD88 Mutated WM and ABC DLBCL Cells That Is Accompanied By ERK1/2 Hyperactivation, and Is Targeted By the Addition of the ERK1/2 Inhibitor Ulixertinib

Jiaji G Chen, Xia Liu, MD, Jie Chen, PhD, Lian Xu, Nicholas Tsakmaklis, Maria Demos, Christopher J Patterson, MFA, Jorge J. Castillo, MD, Zachary Hunter, PhD, Steven P Treon, MD PhD, Guang Yang, PhD

Blood (2016) 128 (22): 2764.

https://doi.org/10.1182/blood.V128.22.2764.2764

Published: 2016

Journal Articles

HCK Transcription Is Regulated By AP1, NF-Kb and STAT3 Transcription Factors in MYD88 Mutated WM and ABC-DLBCL Cells

Xia Liu, MD, Jiaji G Chen, Jie Chen, PhD, Lian Xu, Nicholas Tsakmaklis, Maria Demos, Christopher J Patterson, MFA, Jorge J. Castillo, MD, Zachary Hunter, PhD, Steven P Treon, MD PhD, Guang Yang, PhD

Blood (2016) 128 (22): 2931.

https://doi.org/10.1182/blood.V128.22.2931.2931

Published: 2016

Journal Articles

Prospective, Multicenter Clinical Trial of Everolimus As Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214)

Steven P Treon, MD PhD, Kirsten Meid, MPH, Christina K. Tripsas, MA, Leonard T. Heffner, MD, Herbert Eradat, Ashraf Z Badros, MD, Lian Xu, Zachary Hunter, PhD, Guang Yang, PhD, Christopher J Patterson, MFA, Joshua Gustine, MPH, Jorge J. Castillo, MD, Jeffrey V. Matous, MD, Irene M. Ghobrial, MD

Blood (2016) 128 (22): 4487.

https://doi.org/10.1182/blood.V128.22.4487.4487

Published: 2016

Journal Articles

Molecular Basis of Ibrutinib Resistance in Waldenstrom's Macroglobulinemia

Lian Xu, Nicholas Tsakmaklis, Guang Yang, PhD, Jiaji G Chen, Xia Liu, MD, Jie Chen, PhD, Maria Demos, Christopher J Patterson, MFA, Toni Dubeau, NP, Kirsten Meid, MPH, Joshua Gustine, MPH, Jorge J. Castillo, MD, Ranjana H Advani, MD, Maria Lia Palomba, MD, Richard R. Furman, MD, Zachary Hunter, PhD, Steven P Treon, MD PhD

Blood (2016) 128 (22): 756.

https://doi.org/10.1182/blood.V128.22.756.756

Published: 2016

Journal Articles

Mutated MYD88 Zygosity and CXCR4 Mutation Status Are Important Determinants of Ibrutinib Response and Progression Free Survival in Waldenstrom's Macroglobulinemia

Steven P Treon, MD PhD, Nicholas Tsakmaklis, Kirsten Meid, MPH, Guang Yang, PhD, Jiaji G Chen, Xia Liu, MD, Jie Chen, PhD, Maria Demos, Christopher J Patterson, MFA, Toni Dubeau, NP, Joshua Gustine, MPH, Jorge J. Castillo, MD, Ranjana H Advani, MD, Maria Lia Palomba, MD, Lian Xu, Zachary Hunter, PhD

Blood (2016) 128 (22): 2984.

https://doi.org/10.1182/blood.V128.22.2984.2984

Published: 2016

Journal Articles

Next Generation Sequencing Identifies a Distinct Transcriptional Profile, Including Isoform Dysregulation That Segue with Genomic Alterations in Waldenstrom's Macoglobulinemia

Zachary Hunter, PhD, Lian Xu, Guang Yang, PhD, Nicholas Tsakmaklis, Xia Liu, MD, Jie Chen, PhD, Robert R Manning, Jiaji Chen, Christopher J Patterson, MFA, Jorge J Castillo, MD, Kenneth C Anderson, MD, Nikhil C. Munshi, MD, Steven P Treon, MD PhD

Blood (2015) 126 (23): 128.

https://doi.org/10.1182/blood.V126.23.128.128

Published: 2015

Journal Articles

Whole Genome and Transcriptome Analysis of Waldenstrom's Cell Lines Show Preservation of Many Important Genomic Features of Primary Disease, and Identify a Non-L265P Mutation in MYD88

Zachary Hunter, PhD, Yang Cao, MD, Guang Yang, PhD, Xia Liu, MD, Jie Chen, PhD, Lian Xu, Nicholas Tsakmaklis, Jiaji Chen, Christopher J Patterson, MFA, Jorge J Castillo, MD, Steven P Treon, MD PhD

Blood (2015) 126 (23): 2665.

https://doi.org/10.1182/blood.V126.23.2665.2665

Published: 2015

Journal Articles

Defining the Incidence, Pathology and Clinical Outcomes of Kidney Disease Related to Waldenstrom's Macroglobulinemia and IgM MGUS

Josephine M. Vos, MD, Robert R Manning, Kirsten Meid, MPH, Joshua Gustine, MPH, Christopher J Patterson, MFA, Philip Brodsky, Sandra Kanan, NP, RN, MSN, Marie José Kersten, MD PhD, Steven P Treon, MD PhD, Jorge J Castillo, MD

Blood (2015) 126 (23): 3926.

https://doi.org/10.1182/blood.V126.23.3926.3926

Published: 2015

Journal Articles

Targeting IRAK1/IRAK4 Signaling in Waldenstrom's Macroglobulinemia

Guang Yang, PhD, Xia Liu, MD, Jie Chen, PhD, Lian Xu, Nicholas Tsakmaklis, Jiaji Chen, Christopher J Patterson, MFA, Jorge J Castillo, MD, Philip Cohen, Li Tan, PhD, Sara Buhrlage, PhD, Nathanael Gray, PhD, Steven P Treon, MD PhD

Blood (2015) 126 (23): 4004.

https://doi.org/10.1182/blood.V126.23.4004.4004

Published: 2015

Journal Articles

HCK Is a Highly Relevant Target of Ibrutinib in MYD88 Mutated Waldenstrom's Macroglobulinemia and Diffuse Large B-Cell Lymphoma

Guang Yang, PhD, Sara Buhrlage, PhD, Li Tan, PhD, Xia Liu, MD, Jie Chen, PhD, Zachary Hunter, PhD, Lian Xu, Nicholas Tsakmaklis, Jiaji Chen, Christopher J Patterson, MFA, Jorge J Castillo, MD, Wei Zhang, PhD, Nathanael Gray, PhD, Steven P Treon, MD PhD

Blood (2015) 126 (23): 705.

https://doi.org/10.1182/blood.V126.23.705.705

Published: 2015

Journal Articles

Targeting Myddosome Self-Assembly in Waldenstrom's Macroglobulinemia

Xia Liu, MD, Zachary Hunter, PhD, Lian Xu, Jie Chen, PhD, Jiaji Chen, Nicholas Tsakmaklis, Christopher J Patterson, MFA, Jorge J Castillo, MD, Sara Buhrlage, PhD, Nathanael Gray, PhD, Steven P Treon, MD PhD, Guang Yang, PhD

Blood (2015) 126 (23): 1563.

https://doi.org/10.1182/blood.V126.23.1563.1563

Published: 2015

Journal Articles

Long-Term Outcome of a Prospective Study of Bortezomib, Dexamethasone and Rituximab (BDR) in Previously Untreated, Symptomatic Patients with Waldenstrom's Macroglobulinemia

Steven P Treon, MD PhD, Kirsten Meid, MPH, Joshua Gustine, MPH, Christopher J Patterson, MFA, Jeffrey V. Matous, MD, Irene M. Ghobrial, MD, Jorge J Castillo, MD

Blood (2015) 126 (23): 1833.

https://doi.org/10.1182/blood.V126.23.1833.1833

Published: 2015

NARROW

Acquisition of BTK C481S Produces Resistance to Ibrutinib in MYD88 Mutated WM and ABC DLBCL Cells That Is Accompanied By ERK1/2 Hyperactivation, and Is Targeted By the Addition of the ERK1/2 Inhibitor Ulixertinib

HCK Transcription Is Regulated By AP1, NF-Kb and STAT3 Transcription Factors in MYD88 Mutated WM and ABC-DLBCL Cells

Prospective, Multicenter Clinical Trial of Everolimus As Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214)

Molecular Basis of Ibrutinib Resistance in Waldenstrom's Macroglobulinemia

Mutated MYD88 Zygosity and CXCR4 Mutation Status Are Important Determinants of Ibrutinib Response and Progression Free Survival in Waldenstrom's Macroglobulinemia

Next Generation Sequencing Identifies a Distinct Transcriptional Profile, Including Isoform Dysregulation That Segue with Genomic Alterations in Waldenstrom's Macoglobulinemia

Whole Genome and Transcriptome Analysis of Waldenstrom's Cell Lines Show Preservation of Many Important Genomic Features of Primary Disease, and Identify a Non-L265P Mutation in MYD88

Defining the Incidence, Pathology and Clinical Outcomes of Kidney Disease Related to Waldenstrom's Macroglobulinemia and IgM MGUS

Targeting IRAK1/IRAK4 Signaling in Waldenstrom's Macroglobulinemia

HCK Is a Highly Relevant Target of Ibrutinib in MYD88 Mutated Waldenstrom's Macroglobulinemia and Diffuse Large B-Cell Lymphoma

Targeting Myddosome Self-Assembly in Waldenstrom's Macroglobulinemia

Long-Term Outcome of a Prospective Study of Bortezomib, Dexamethasone and Rituximab (BDR) in Previously Untreated, Symptomatic Patients with Waldenstrom's Macroglobulinemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only